The Journal of Neuroimmune Pharmacology (JNIP) is the peer-reviewed journal of the Society on NeuroImmune Pharmacology. JNIP interfaces the disciplines of immunology, pharmacology and experimental neuroscience by acting as a platform for research discoveries into the pathogenesis and pharmacology of nervous system disorders affecting the immune system and vice versa. Original interdisciplinary scientific contributions, concise "opinion," and broad reviews are welcome. Research areas reporting in JNIP include receptor cell signaling, the pathobiology, cognitive neuroscience, psychopharmacology and immunity of drugs of abuse, neurodegenerative disorders, neurovirology, neuroimmunology, and neuropharmacology. Manuscripts must include original research linked to the immunology and pharmacology of human neurologic and neuropsychiatric disorders including substance abuse, depression, psychosis, Alzheimer's and Parkinson's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, HIV-associated neurocognitive disorders, neuroendocrine and microbial infections, and immunological, toxic and metabolic disorders of the brain, spinal cord, and peripheral nerves. Topical studies of brain-immune interactions include, but are not limited to: (1) leukocyte trafficking into the nervous system; (2) innate immunity in the nervous system; (3) pathophysiology of neurodegenerative diseases; (4) effects of endogenous ligands on brain-immune interactions (neuronal-peripheral immune; neuronal-glial); (5) effects of drugs of abuse and other pharmacophores on peripheral immune responses, (6) medicinal chemistry and drug development; (7) vaccine approaches for neurologic and neuropsychiatric diseases; (8) bioimaging and proteomics; (9) nanomedicine; and (10) immune surveillance for microbial infections. JNIP will identify novel pharmacologic discoveries (organized action of drug targets, mechanisms, and development) of brain-immune interactions with a potential towards modif ying the cellular and systemic responses that affect disease or lead to amelioration of brain injury and immune dysfunction.

Journal information

  • Howard Gendelman
Publishing model
Hybrid (Transformative Journal). Learn about publishing Open Access with us

Journal metrics

4.113 (2019)
Impact factor
4.179 (2019)
Five year impact factor
32 days
Submission to first decision
103 days
Submission to acceptance
150,116 (2020)

Latest articles

This journal has 72 open access articles

Journal updates

  • Announcement: COVID-19 impact on peer review

    As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

View all updates

Societies, partners and affiliations


Note this is only the net price. Taxes will be calculated during checkout.
  • Immediate online access with complete access to all articles starting 1997
  • Downloadable in PDF format
  • Subscription expires 12/31/2021

About this journal

Electronic ISSN
Print ISSN
Abstracted and indexed in
  3. Biological Abstracts
  4. CNKI
  5. Dimensions
  6. EBSCO Biomedical Reference Collection
  7. EBSCO Discovery Service
  9. Google Scholar
  10. Institute of Scientific and Technical Information of China
  11. Japanese Science and Technology Agency (JST)
  12. Journal Citation Reports/Science Edition
  13. Medline
  14. Meta
  15. Naver
  16. OCLC WorldCat Discovery Service
  17. Pathway Studio
  18. ProQuest Central
  19. ProQuest Health & Medical Collection
  20. ProQuest Health Research Premium Collection
  21. ProQuest Medical Database
  22. ProQuest-ExLibris Primo
  23. ProQuest-ExLibris Summon
  24. Reaxys
  25. SCImago
  26. SCOPUS
  27. Science Citation Index Expanded (SciSearch)
  28. TD Net Discovery Service
  29. UGC-CARE List (India)
Copyright information

Rights and permissions

Springer policies

© Springer Science+Business Media, LLC, part of Springer Nature